Patents by Inventor Zi-Hua Jiang
Zi-Hua Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10988500Abstract: The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.Type: GrantFiled: December 16, 2019Date of Patent: April 27, 2021Assignee: Immunovaccine Technologies Inc.Inventors: Zi-hua Jiang, Jordan David Lewicky, Genevieve Mary Weir, Rajkannan Rajagopalan, Leeladhar Sammatur, Marianne Michelle Stanford, Marc Mansour
-
Patent number: 10533033Abstract: The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.Type: GrantFiled: December 11, 2015Date of Patent: January 14, 2020Assignee: IMMUNOVACCINE TECHNOLOGIES INC.Inventors: Zi-hua Jiang, Jordan David Lewicky, Genevieve Mary Weir, Rajkannan Rajagopalan, Leeladhar Sammatur, Marianne Michelle Stanford, Marc Mansour
-
Publication number: 20180009833Abstract: The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.Type: ApplicationFiled: December 11, 2015Publication date: January 11, 2018Applicant: Immunovaccine Technologies Inc.Inventors: Zi-hua Jiang, Jordan David Lewicky, Genevieve Mary Weir, Rajkannan Rajagopalan, Leeladhar Sammatur, Marianne Michelle Stanford, Marc Mansour
-
Patent number: 8097593Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: GrantFiled: June 30, 2010Date of Patent: January 17, 2012Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Publication number: 20120003295Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: ApplicationFiled: June 30, 2010Publication date: January 5, 2012Applicant: ONCOTHYREON INC.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Patent number: 7820627Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: GrantFiled: May 9, 2003Date of Patent: October 26, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Patent number: 7741297Abstract: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.Type: GrantFiled: February 4, 2003Date of Patent: June 22, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, Rao Koganty, Damayanthi Yalamati, Myung-Gi Baek
-
Patent number: 7491707Abstract: New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R1, R4 and R5 are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.Type: GrantFiled: November 15, 2000Date of Patent: February 17, 2009Assignee: Biomira, Inc.Inventors: Zi-Hua Jiang, Mimi Bach, Damayanthi Yalamati, Rao Koganty, Michael Longenecker
-
Publication number: 20060189550Abstract: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.Type: ApplicationFiled: February 4, 2003Publication date: August 24, 2006Applicant: Biomira Inc.Inventors: Zi-Hua Jiang, Rao Koganty, Damayanthi Yalamati, Myung-Gi Baek
-
Publication number: 20060116331Abstract: Glycosylceramide analogues are disclosed in which the ceramide moiety and optionally the carbohydrate moiety are modified or replaced. These analogues are useful as immunomodulators, antitumor agents, and as other pharmaceutical agents.Type: ApplicationFiled: September 29, 2003Publication date: June 1, 2006Applicant: BIOMIRA, INC.Inventors: Zi-Hua Jiang, Sham Gandhi, R. Koganty
-
Publication number: 20060069238Abstract: A glycolipopeptide comprising at least one disease-associated epitope, and characterized by at least one lipidated interior amino acid or by the presence of a MUC1 epitope, may be used in a vaccine, preferably in conjunction with a liposome.Type: ApplicationFiled: April 9, 2003Publication date: March 30, 2006Applicant: Biomira, Inc.Inventors: R. Koganty, Zi-Hua Jiang, Damayanthi Yalamati, Sham Sandhi, Wladyslaw Budzynski, Mark Krantz, B. Longenecker
-
Publication number: 20060040891Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: ApplicationFiled: May 9, 2003Publication date: February 23, 2006Applicant: Biomira, IncInventors: Zi-Hua Jiang, R Koganty, Wladyslaw Budzynski